SEC Form 4 · accession 0000899243-19-003337
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — See Remarks · Director
Period of report
Feb 8, 2019
Accepted (ET)
Feb 12, 2019 · 6:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 8, 2019 | M | 1,400 | $12.16 | A | 734,013 | D | |
| Common StockF3,F1 | Feb 8, 2019 | S | 1,400 | $67.08 | D | 732,613 | D | |
| Common StockF1 | Feb 8, 2019 | M | 3,571 | $12.16 | A | 736,184 | D | |
| Common StockF4,F1 | Feb 8, 2019 | S | 3,571 | $66.32 | D | 732,613 | D | |
| Common StockF1 | Feb 8, 2019 | M | 7,100 | $12.16 | A | 739,713 | D | |
| Common StockF5,F1 | Feb 8, 2019 | S | 7,100 | $65.00 | D | 732,613 | D | |
| Common StockF1 | Feb 8, 2019 | M | 8,077 | $12.16 | A | 740,690 | D | |
| Common StockF6,F1 | Feb 8, 2019 | S | 8,077 | $64.49 | D | 732,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Feb 8, 2019 | M | 1,400 | D | — | Aug 25, 2019 | Common Stock | 1,400 | 139,637 | D |
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Feb 8, 2019 | M | 3,571 | D | — | Aug 25, 2019 | Common Stock | 3,571 | 136,066 | D |
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Feb 8, 2019 | M | 7,100 | D | — | Aug 25, 2019 | Common Stock | 7,100 | 128,966 | D |
| Non-Qualified Stock Option (right to buy)F7 | $12.16 | Feb 8, 2019 | M | 8,077 | D | — | Aug 25, 2019 | Common Stock | 8,077 | 120,889 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $66.84 to $67.43. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $65.83 to $66.80. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of common stock executed in multiple transactions at prices ranging from $64.73 to $65.62. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Reflects sales of common stock executed in multiple transactions at prices ranging from $63.72 to $64.71. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F7Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.
Remarks
President and CEO 8025 - Executive